NASDAQ:VCEL Vericel (VCEL) Stock Price, News & Analysis $41.85 +0.50 (+1.21%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$41.30 -0.55 (-1.31%) As of 05/30/2025 04:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Vericel Stock (NASDAQ:VCEL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vericel alerts:Sign Up Key Stats Today's Range$40.54▼$42.1250-Day Range$37.92▼$46.4252-Week Range$37.39▼$63.00Volume715,515 shsAverage Volume414,362 shsMarket Capitalization$2.11 billionP/E Ratio697.62Dividend YieldN/APrice Target$61.14Consensus RatingBuy Company OverviewVericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.Read More… Vericel Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreVCEL MarketRank™: Vericel scored higher than 62% of companies evaluated by MarketBeat, and ranked 431st out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingVericel has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVericel has only been the subject of 2 research reports in the past 90 days.Read more about Vericel's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth214.29% Earnings GrowthEarnings for Vericel are expected to grow by 214.29% in the coming year, from $0.14 to $0.44 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vericel is 697.62, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.27.Price to Earnings Ratio vs. SectorThe P/E ratio of Vericel is 697.62, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.05.Price to Book Value per Share RatioVericel has a P/B Ratio of 8.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Vericel's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted9.02% of the float of Vericel has been sold short.Short Interest Ratio / Days to CoverVericel has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Vericel has recently decreased by 8.66%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVericel does not currently pay a dividend.Dividend GrowthVericel does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.02% of the float of Vericel has been sold short.Short Interest Ratio / Days to CoverVericel has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Vericel has recently decreased by 8.66%, indicating that investor sentiment is improving significantly. News and Social Media2.8 / 5News Sentiment0.98 News SentimentVericel has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Vericel this week, compared to 6 articles on an average week.Search Interest2 people have searched for VCEL on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Vericel insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,258,348.00 in company stock.Percentage Held by InsidersOnly 5.20% of the stock of Vericel is held by insiders.Read more about Vericel's insider trading history. Receive VCEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vericel and its competitors with MarketBeat's FREE daily newsletter. Email Address VCEL Stock News HeadlinesVericel (NASDAQ:VCEL) Earns Overweight Rating from StephensMay 25, 2025 | americanbankingnews.com5VCEL : What Analysts Are Saying About Vericel StockMay 23, 2025 | benzinga.com"I'm risking my reputation on this"Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.June 1, 2025 | Crypto 101 Media (Ad)Vericel at BofA Securities Conference: Growth and Innovation in HealthcareMay 17, 2025 | investing.comVericel Corporation: Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability GuidanceMay 9, 2025 | finanznachrichten.deVericel Corp (VCEL) Q1 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ...May 9, 2025 | finance.yahoo.comVericel Corporation 2025 Q1 - Results - Earnings Call PresentationMay 8, 2025 | seekingalpha.comVericel Corporation (VCEL) Q1 2025 Earnings Conference Call TranscriptMay 8, 2025 | seekingalpha.comSee More Headlines VCEL Stock Analysis - Frequently Asked Questions How have VCEL shares performed this year? Vericel's stock was trading at $54.91 at the beginning of 2025. Since then, VCEL stock has decreased by 23.8% and is now trading at $41.85. View the best growth stocks for 2025 here. How were Vericel's earnings last quarter? Vericel Co. (NASDAQ:VCEL) released its earnings results on Thursday, May, 8th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by $0.14. The firm's revenue was up 2.6% compared to the same quarter last year. Read the conference call transcript. Who are Vericel's major shareholders? Top institutional investors of Vericel include Vanguard Group Inc. (6.97%), Invesco Ltd. (4.53%), Conestoga Capital Advisors LLC (4.11%) and Congress Asset Management Co. (2.95%). Insiders that own company stock include Dominick Colangelo, Jonathan Mark Hopper, Paul K Wotton, Robert L Md Zerbe, Joseph Anthony Mara Jr, Steven C Gilman, Jonathan Siegal, Michael Halpin and Sean C Flynn. View institutional ownership trends. How do I buy shares of Vericel? Shares of VCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vericel own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vericel investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Palo Alto Networks (PANW) and Netflix (NFLX). Company Calendar Last Earnings5/08/2025Today6/01/2025Next Earnings (Estimated)8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VCEL CIK887359 Webwww.vcel.com Phone(617) 588-5555Fax617-588-5554Employees300Year Founded1989Price Target and Rating Average Stock Price Target$61.14 High Stock Price Target$67.00 Low Stock Price Target$51.00 Potential Upside/Downside+46.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)$0.03 Trailing P/E Ratio697.62 Forward P/E Ratio298.93 P/E GrowthN/ANet Income-$3.18 million Net Margins1.56% Pretax Margin2.05% Return on Equity1.48% Return on Assets0.96% Debt Debt-to-Equity RatioN/A Current Ratio4.61 Quick Ratio4.23 Sales & Book Value Annual Sales$238.54 million Price / Sales8.83 Cash Flow$0.01 per share Price / Cash Flow3,081.95 Book Value$4.73 per share Price / Book8.85Miscellaneous Outstanding Shares50,343,000Free Float46,791,000Market Cap$2.11 billion OptionableOptionable Beta1.31 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (NASDAQ:VCEL) was last updated on 6/1/2025 by MarketBeat.com Staff From Our PartnersBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredTrump Just Gave the Green Light to Rewrite Social Security?In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredThe “supermetal” that could power AIWhile the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the stor...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredThe Buffett Indicator is screaming, “sell stocks, buy gold”A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vericel Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vericel With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.